ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

SSTR2-targeting Non-peptide Drug Conjugate CRN09682

Its studies are mostly in Neuroendocrine Tumors, led by Vertex Pharmaceuticals.

Furthest: phase 2, since Jul 1, 20251 company-led study, 1 open or runningNext primary completion: Aug 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Vertex Pharmaceuticals11 open or runningphase 2since Jul 1, 2025Jul 1, 2025Aug 2027phase 2 · NCT07129252

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 1, 2025First study: phase 2 study in Neuroendocrine TumorsFirst studyNCT07129252 · 150 enrolled · United States, Spain

Ahead

  1. Aug 2027Primary completion: phase 2 study in Neuroendocrine TumorsNCT07129252

TargetBeta

SSTR2 →read by rule
“A non-peptide drug conjugate composed of a non-peptide somatostatin receptor 2 (SSTR2) agonist ”NCIt, by rule

Other programs on SSTR2

ProgramCompanyFurthest phaseStudies
OctreotideruleNovartisphase 436
PaltusotineruleVertex Pharmaceuticalsphase 39
actinium AC-225 dotatateBristol-Myers Squibbphase 33
Actinium Ac 225 SSTR2-targeted Agent RYZ401Bristol-Myers Squibbphase 11
NTQ6179Sino Biopharmaceuticalphase 11

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07129252Neuroendocrine Tumors · United States, Spain2Active, not recruitingAug 2027150

How it is read

Names in the registry

  • “CRN09682”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.